Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study-Reference-Cited by-同舟云学术

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Published:2015-03 Issue:9973 Volume:385 Page:1107-1113
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kohli Anita,Osinusi Anuoluwapo,Sims Zayani,Nelson Amy,Meissner Eric G,Barrett Lisa L,Bon Dimitra,Marti Miriam M,Silk Rachel,Kotb Colleen,Gross Chloe,Jolley Tim A,Sidharthan Sreetha,Petersen Tess,Townsend Kerry,Egerson D'Andrea,Kapoor Rama,Spurlin Emily,Sneller Michael,Proschan Michael,Herrmann Eva,Kwan Richard,Teferi Gebeyehu,Talwani Rohit,Diaz Gabbie,Kleiner David E,Wood Brad J,Chavez Jose,Abbott Stephen,Symonds William T,Subramanian G Mani,Pang Phillip S,McHutchison John,Polis Michael A,Fauci Anthony S,Masur Henry,Kottilil Shyam

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome;Alter;Semin Liver Dis,2000

3. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial;Kowdley;Lancet,2013

4. Response-guided telaprevir combination treatment for hepatitis C virus infection;Sherman;N Engl J Med,2011

5. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial;Kwo;Lancet,2010

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs;Cell Chemical Biology;2024-04

2. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus;Current Medicinal Chemistry;2023-10-19

3. Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C;Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation;2023-09-20

4. Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals;APMIS;2023-06-25

5. Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus;The Journal of Infectious Diseases;2023-02-01